세계의 방사면역치료 시장 : 시장 점유율 및 순위, 전체 판매 및 수요 예측(2024-2030년)

The global market for Radioimmunotherapy was estimated to be worth US$ 1865 million in 2023 and is forecast to a readjusted size of US$ 5408 million by 2030 with a CAGR of 14.63% during the forecast period 2024-2030.

North American market for Radioimmunotherapy was valued at $ 1100 million in 2023 and will reach $ 3274 million by 2030, at a CAGR of 14.13% during the forecast period of 2024 through 2030.

Asia-Pacific market for Radioimmunotherapy was valued at $ 171.72 million in 2023 and will reach $ 534.7 million by 2030, at a CAGR of 18.84% during the forecast period of 2024 through 2030.

Europe market for Radioimmunotherapy was valued at $ 574.41 million in 2023 and will reach $ 1581.23 million by 2030, at a CAGR of 14.48% during the forecast period of 2024 through 2030.

The global key companies of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately 99.45% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Radioimmunotherapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Radioimmunotherapy by region & country, by Type, and by Application.

The Radioimmunotherapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioimmunotherapy.

Market Segmentation

By Company

• Bayer
• Novartis
• Lantheus
• Aurobindo Pharma
• Mundipharma
• China Isotope & Radiation
• Curium Pharmaceuticals
• Gilead Sciences
• Clarity Pharmaceuticals
• Curasight
• Nordic Nanovector
• Philogen
• RadioMedix
• Telix Pharmaceuticals
• Orano Med
• Actinium Pharmaceuticals
• Y-mAbs Therapeutics
• Fusion Pharmaceuticals

Segment by Type

• Beta-emitting
• Targeted Alpha Therapy

Segment by Application

• Solid Tumor
• Non Hodgkin Lymphoma

By Region

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Other
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Rest of Europe
• South America
• Brazil
• Rest of South America
• Middle East & Africa
• Middle East
• Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Radioimmunotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Radioimmunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Radioimmunotherapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Radioimmunotherapy Product Introduction
• 1.2 Global Radioimmunotherapy Market Size Forecast (2019-2030)
• 1.3 Radioimmunotherapy Market Trends & Drivers
  • 1.3.1 Radioimmunotherapy Industry Trends
  • 1.3.2 Radioimmunotherapy Market Drivers & Opportunity
  • 1.3.3 Radioimmunotherapy Market Challenges
  • 1.3.4 Radioimmunotherapy Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Radioimmunotherapy Players Revenue Ranking (2023)
• 2.2 Global Radioimmunotherapy Revenue by Company (2019-2024)
• 2.3 Key Companies Radioimmunotherapy Area Served and Headquarters
• 2.4 Key Companies Radioimmunotherapy Product Offered
• 2.5 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
• 2.6 Radioimmunotherapy Market Competitive Analysis
  • 2.6.1 Radioimmunotherapy Market Concentration Rate (2019-2024)
  • 2.6.2 Global 5 Largest Companies by Radioimmunotherapy Revenue in 2023
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2023)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Beta-emitting
  • 3.1.2 Targeted Alpha Therapy
• 3.2 Global Radioimmunotherapy Sales Value by Type
  • 3.2.1 Global Radioimmunotherapy Sales Value by Type (2019 VS 2023 VS 2030)
  • 3.2.2 Global Radioimmunotherapy Sales Value, by Type (2019-2030)
  • 3.2.3 Global Radioimmunotherapy Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Solid Tumor
  • 4.1.2 Non Hodgkin Lymphoma
• 4.2 Global Radioimmunotherapy Sales Value by Application
  • 4.2.1 Global Radioimmunotherapy Sales Value by Application (2019 VS 2023 VS 2030)
  • 4.2.2 Global Radioimmunotherapy Sales Value, by Application (2019-2030)
  • 4.2.3 Global Radioimmunotherapy Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

• 5.1 Global Radioimmunotherapy Sales Value by Region
  • 5.1.1 Global Radioimmunotherapy Sales Value by Region: 2019 VS 2023 VS 2030
  • 5.1.2 Global Radioimmunotherapy Sales Value by Region (2019-2024)
  • 5.1.3 Global Radioimmunotherapy Sales Value by Region (2025-2030)
  • 5.1.4 Global Radioimmunotherapy Sales Value by Region (%), (2019-2030)
• 5.2 North America
  • 5.2.1 North America Radioimmunotherapy Sales Value, 2019-2030
  • 5.2.2 North America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
• 5.3 Europe
  • 5.3.1 Europe Radioimmunotherapy Sales Value, 2019-2030
  • 5.3.2 Europe Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030
  • 5.4.2 Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2023 VS 2030
• 5.5 South America
  • 5.5.1 South America Radioimmunotherapy Sales Value, 2019-2030
  • 5.5.2 South America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Radioimmunotherapy Sales Value, 2019-2030
  • 5.6.2 Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Radioimmunotherapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
• 6.2 Key Countries/Regions Radioimmunotherapy Sales Value, 2019-2030
• 6.3 North America
  • 6.3.1 North America Radioimmunotherapy Sales Value, 2019-2030
  • 6.3.2 North America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.3.3 North America Radioimmunotherapy Sales Value by Application, 2023 VS 2030
• 6.4 Europe
  • 6.4.1 Europe Radioimmunotherapy Sales Value, 2019-2030
  • 6.4.2 Europe Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.4.3 Europe Radioimmunotherapy Sales Value by Application, 2023 VS 2030
• 6.5 Asia Pacific
  • 6.5.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030
  • 6.5.2 Asia Pacific Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.5.3 Asia Pacific Radioimmunotherapy Sales Value by Application, 2023 VS 2030
• 6.6 South America
  • 6.6.1 South America Radioimmunotherapy Sales Value, 2019-2030
  • 6.6.2 South America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.6.3 South America Radioimmunotherapy Sales Value by Application, 2023 VS 2030
• 6.7 Middle East and Africa
  • 6.7.1 Middle East and Africa Radioimmunotherapy Sales Value, 2019-2030
  • 6.7.2 Middle East and Africa Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.7.3 Middle East and Africa Radioimmunotherapy Sales Value by Application, 2023 VS 2030

7 Company Profiles

• 7.1 Bayer
  • 7.1.1 Bayer Company Details
  • 7.1.2 Bayer Business Overview
  • 7.1.3 Bayer Radioimmunotherapy Products and Services
  • 7.1.4 Bayer Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.1.5 Bayer Radioimmunotherapy SWOT Analysis
  • 7.1.6 Bayer Business Strategy
• 7.2 Novartis
  • 7.2.1 Novartis Company Details
  • 7.2.2 Novartis Business Overview
  • 7.2.3 Novartis Radioimmunotherapy Products and Services
  • 7.2.4 Novartis Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.2.5 Novartis Radioimmunotherapy SWOT Analysis
  • 7.2.6 Novartis Business Strategy
• 7.3 Lantheus
  • 7.3.1 Lantheus Company Details
  • 7.3.2 Lantheus Business Overview
  • 7.3.3 Lantheus Radioimmunotherapy Products and Services
  • 7.3.4 Lantheus Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.3.5 Lantheus Radioimmunotherapy SWOT Analysis
  • 7.3.6 Lantheus Business Strategy
• 7.4 Aurobindo Pharma
  • 7.4.1 Aurobindo Pharma Company Details
  • 7.4.2 Aurobindo Pharma Business Overview
  • 7.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services
  • 7.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis
  • 7.4.6 Aurobindo Pharma Business Strategy
• 7.5 Mundipharma
  • 7.5.1 Mundipharma Company Details
  • 7.5.2 Mundipharma Business Overview
  • 7.5.3 Mundipharma Radioimmunotherapy Products and Services
  • 7.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.5.5 Mundipharma Business Strategy
• 7.6 China Isotope & Radiation
  • 7.6.1 China Isotope & Radiation Company Details
  • 7.6.2 China Isotope & Radiation Business Overview
  • 7.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services
  • 7.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis
  • 7.6.6 China Isotope & Radiation Business Strategy
• 7.7 Curium Pharmaceuticals
  • 7.7.1 Curium Pharmaceuticals Company Details
  • 7.7.2 Curium Pharmaceuticals Business Overview
  • 7.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis
  • 7.7.6 Curium Pharmaceuticals Business Strategy
• 7.8 Gilead Sciences
  • 7.8.1 Gilead Sciences Company Details
  • 7.8.2 Gilead Sciences Business Overview
  • 7.8.3 Gilead Sciences Radioimmunotherapy Products and Services
  • 7.8.4 Gilead Sciences Business Strategy
• 7.9 Clarity Pharmaceuticals
  • 7.9.1 Clarity Pharmaceuticals Company Details
  • 7.9.2 Clarity Pharmaceuticals Business Overview
  • 7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis
  • 7.9.5 Clarity Pharmaceuticals Business Strategy
• 7.10 Curasight
  • 7.10.1 Curasight Company Details
  • 7.10.2 Curasight Business Overview
  • 7.10.3 Curasight Radioimmunotherapy Products and Services
  • 7.10.4 Curasight Radioimmunotherapy SWOT Analysis
  • 7.10.5 Curasight Business Strategy
• 7.11 Nordic Nanovector
  • 7.11.1 Nordic Nanovector Company Details
  • 7.11.2 Nordic Nanovector Business Overview
  • 7.11.3 Nordic Nanovector Radioimmunotherapy Products and Services
  • 7.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis
  • 7.11.5 Nordic Nanovector Business Strategy
• 7.12 Philogen
  • 7.12.1 Philogen Company Details
  • 7.12.2 Philogen Business Overview
  • 7.12.3 Philogen Radioimmunotherapy Products and Services
  • 7.12.4 Philogen Radioimmunotherapy SWOT Analysis
  • 7.12.5 Philogen Business Strategy
• 7.13 RadioMedix
  • 7.13.1 RadioMedix Company Details
  • 7.13.2 RadioMedix Business Overview
  • 7.13.3 RadioMedix Radioimmunotherapy Products and Services
  • 7.13.4 RadioMedix Business Strategy
• 7.14 Telix Pharmaceuticals
  • 7.14.1 Telix Pharmaceuticals Company Details
  • 7.14.2 Telix Pharmaceuticals Business Overview
  • 7.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis
  • 7.14.5 Telix Pharmaceuticals Business Strategy
• 7.15 Orano Med
  • 7.15.1 Orano Med Company Details
  • 7.15.2 Orano Med Business Overview
  • 7.15.3 Orano Med Radioimmunotherapy Products and Services
  • 7.15.4 Orano Med Radioimmunotherapy SWOT Analysis
  • 7.15.5 Orano Med Business Strategy
• 7.16 Actinium Pharmaceuticals
  • 7.16.1 Actinium Pharmaceuticals Company Details
  • 7.16.2 Actinium Pharmaceuticals Business Overview
  • 7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis
  • 7.16.5 Actinium Pharmaceuticals Business Strategy
• 7.17 Y-mAbs Therapeutics
  • 7.17.1 Y-mAbs Therapeutics Company Details
  • 7.17.2 Y-mAbs Therapeutics Business Overview
  • 7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services
  • 7.17.4 Y-mAbs Therapeutics Business Strategy
• 7.18 Fusion Pharmaceuticals
  • 7.18.1 Fusion Pharmaceuticals Company Details
  • 7.18.2 Fusion Pharmaceuticals Business Overview
  • 7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.18.4 Fusion Pharmaceuticals Business Strategy

8 Industry Chain Analysis

• 8.1 Radioimmunotherapy Industrial Chain
• 8.2 Radioimmunotherapy Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Radioimmunotherapy Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Radioimmunotherapy Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
  • 10.1.2 Data Source
• 10.2 Author Details
• 10.3 Disclaimer